Toggle navigation
Home
Psoriasis Models
In Vitro
Psoriasis Models
2D Psoriasis Models
3D Psoriasis Models
Ex Vivo
Psoriasis Models
TH17-Driven
Ex Vivo
Human Psoriasis Models
Ex Vivo
Skin/T Cell Co-culture Models
Imiquimod-Induced
Ex Vivo
Model of Psoriatic Human Skin
In Vivo
Psoriasis Models
Spontaneous Models of Psoriasis
Genetically Engineered Psoriasis Models
Xenotransplantation Model of Psoriasis
Imiquimod-Induced Psoriasis Models
IL-23-Induced Psoriasis Models
Propranolol-Induced Psoriasis-Like Model
Estrogen-Induced Vaginal Epithelium Psoriasis-Like Model
Mannan-Induced Psoriatic Arthritis Models
Humanized Mouse Psoriasis Models
Zebrafish Psoriasis Models
Pig Models of Psoriasis
Drug Discovery
By Drug Modality
Antipsoriatic Small Molecules
Antipsoriatic Therapeutic Antibody
Antipsoriatic Peptides
Nucleic Acid-based Antipsoriatic Therapy
By Target
Cytokine-Targeted Antipsoriatic Drugs
Immune-Targeted Antipsoriatic Drugs
Kinase-Targeted Antipsoriatic Drugs
By Administration Route
Topical Antipsoriatic Drugs
Subcutaneous Antipsoriatic Drugs
Systemic Antipsoriatic Drugs
Oral Antipsoriatic Drugs
By Disease
Plaque Psoriasis
Guttate Psoriasis
Erythrodermic Psoriasis
Pustular Psoriasis
Psoriatic Arthritis
Preclinical Drug Development
Dermatopathology Services
Anti-Psoriatic Efficacy Evaluation
Pharmacokinetic Services
Dermatotoxicology Services
Biomarker Discovery
Extracellular Matrix Biomarker Discovery
Omics-Driven Biomarker Discovery
Virtual Booth
Brochure
Animal Models
Case Study
Protocol
Company
About Us
Contact Us
Careers
Case Study
Home
Virtual Booth
Case Study
Preclinical Efficacy Evaluation of Antipsoriatic Drugs Targeting IL-17
